gene_symbol
UNKNOWN
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
The vaccine primes and expands neoantigen-specific CD8+ T cells via APC presentation; these T cells recognize HLA-I–presented neoepitopes on tumor cells and kill them via perforin/granzyme and Fas–FasL pathways.
enzyme_product
Off
epitope
On
variant
On
isoform
Off
hla_specific
On
gated
Off
other_modifier
CD8+ T-cell targets; HLA class I–restricted; patient-specific multi-epitope
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT05916261
disease_id_num_tar_ref
834
drug_id_num_tar_ref
2302